title: Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation.
abstract: In patients with atrial fibrillation (AF) undergoing coronary stent implantation, the optimal antithrombotic strategy is unclear. We evaluated whether use of oral anticoagulation (OAC) was associated with any benefit in morbidity or mortality in patients with AF, high risk of thromboembolism (TE) (CHA2DS2-VASC score ≥ 2) and coronary stent implantation. Among 8,962 unselected patients with AF seen between 2000 and 2010, a total of 2,709 (30%) had coronary artery disease and 417/2,709 (15%) underwent stent implantation while having CHA2DS2-VASC score ≥ 2. During follow-up (median=650 days), all TE, bleeding episodes, and major adverse cardiac events (i.e. death, acute myocardial infarction, target lesion revascularisation) were recorded. At discharge, 97/417 patients (23%) received OAC, which was more likely to be prescribed in patients with permanent AF and in those treated for elective stent implantation. The incidence of outcome event rates was not significantly different in patients treated and those not treated with OAC. However, in multivariate analysis, the lack of OAC at discharge was independently associated with increased risk of death/stroke/systemic TE (relative risk [RR] =2.18, 95% confidence interval [CI] 1.02-4.67, p=0.04), with older age (RR =1.12, 1.04-1.20, p=0.003), heart failure (RR =3.26, 1.18-9.01, p=0.02), and history of stroke (RR =18.87, 3.11-111.11, p=0.001). In conclusion, in patients with AF and high thromboembolic risk after stent implantation, use of OAC was independently associated with decreased risk of subsequent death/stroke/systemic TE, suggesting that OAC should be systematically used in this patient population.
authors.affiliation: Laurent Fauchier, MD, Service de Cardiologie B et Laboratoire d'Electrophysiologie Cardiaque, Pole Cœur Thorax Vasculaire Hémostase, Centre Hospitalier Universitaire Trousseau, 37044 Tours, France, Tel.: +33 2 47 47 46 50, Fax: +33 2 47 47 59 19, E-mail: lfau@med.univ-tours.fr.
authors.forename: A
authors.initials: A
authors.lastname: Bernard
authors.forename: L
authors.initials: L
authors.lastname: Fauchier
authors.forename: C
authors.initials: C
authors.lastname: Pellegrin
authors.forename: N
authors.initials: N
authors.lastname: Clementy
authors.forename: C
authors.initials: C
authors.lastname: Saint Etienne
authors.forename: A
authors.initials: A
authors.lastname: Banerjee
authors.forename: D
authors.initials: D
authors.lastname: Naudin
authors.forename: D
authors.initials: D
authors.lastname: Angoulvant
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D006348:Cardiac Surgical Procedures / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000737:chemistry; D012044:Regression Analysis; D012307:Risk Factors; D015607:Stents; D013923:Thromboembolism / Q000150:complications / Q000517:prevention & control; D016896:Treatment Outcome; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014812:Vitamin K